ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN.
| Revenue (Most Recent Fiscal Year) | $486.82M |
| Net Income (Most Recent Fiscal Year) | $18.78M |
| PE Ratio (Current Year Earnings Estimate) | 18.47 |
| PE Ratio (Trailing 12 Months) | 16.96 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.84 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.10 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.20 |
| Pre-Tax Margin (Trailing 12 Months) | 4.08% |
| Net Margin (Trailing 12 Months) | 3.86% |
| Return on Equity (Trailing 12 Months) | 18.06% |
| Return on Assets (Trailing 12 Months) | 8.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.81 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.66 |
| Inventory Turnover (Trailing 12 Months) | 1.71 |
| Book Value per Share (Most Recent Fiscal Quarter) | $21.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.78 |
| Earnings per Share (Most Recent Fiscal Year) | $3.85 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 21.08M |
| Free Float | 18.40M |
| Market Capitalization | $1.38B |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 0.79 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 76.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |